In a new job - August 28, 2014
Moberg Pharma US manager leaves post
Moberg Pharma’s head of US operations, Steve Cagle, will resign by the end of January 2015. Steve Cagle has been part of the management team at Moberg Pharma since November 2012. “I am proud of the achievements during the last two years. We have almost doubled the net sales in the U.S. market and made […]
Financing - May 28, 2014
Moberg Pharma completes share issue of SEK 60 million
The company has completed a directed share issue of 2.1 million new shares, which brings SEK 60 million to the company before transaction costs. The new share issue, which was resolved by the Board of the company on May 27th, 2014 with authorization from the Annual General Meeting on May 13th, 2014, includes 2,068,965 new […]
Agreement - April 14, 2014
Moberg Pharma acquires treatment project
Moberg Pharma has acquired the global rights to a novel topical formulation for the treatment of oral pain. The company has announced that it has entered into a definitive agreement with Danish Oracain II Aps to acquire all assets as well as global rights to a novel and patent pending oral formulation of the proven […]
Intellectual Property - March 25, 2014
Moberg Pharma launches new patent formulation
The company will start shipping a new patent pending formulation of Kerasal Nail to customers in the US. According to Moberg Pharma the new product is shipped as a flow-through. It will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass retailers such as Walmart and Target as well as […]
New Market - January 31, 2014
Moberg Pharma gets approval in United Arab Emirates
The company’s partner Leosons International has received approval for Kerasal Nail in UAE. According to Moberg Pharma, launch preparations of the product will start immediately. In October 2013 a distribution agreement was signed sixteen markets in the MENA region (Middle East and North Africa). “We signed the distribution agreement with Leosons just three months ago. The rapid […]
Pharma Business - August 7, 2013
Moberg Pharma extends distribution agreement in China
Menarini Asia-Pacific, a member of the Menarini Group, has been granted the exclusive rights to market and sell Moberg Pharma’s Kerasal Nail on the Chinese market. Kerasal Nail is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis. Since the launch in 2011 it has been launched in […]
